Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation.

Ther Clin Risk Manag · 2014 · PMC3968084 · PMID 24711702

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

There was a strong trend for a reduction in the rate of the primary efficacy endpoint in the per-protocol as-treated population (defined as the composite of stroke and systemic embolism) with rivaroxaban versus warfarin (HR =0.49; P =0.050).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.